Legence Corp. Class A Common stock
LGN
$56.65
+5.79%
Legence Corp. is a provider of engineering, installation, and maintenance services for critical building systems, specializing in complex HVAC, process piping, and mechanical, electrical, and plumbing (MEP) systems for technically demanding facilities in the technology, life sciences, healthcare, and education sectors. The company operates through two reportable segments — Installation and Maintenance, which generates the bulk of revenue, and Engineering and Consulting — and positions itself as a specialist contractor serving the secular build-out of data centers, laboratories, and other high-specification infrastructure. Legence is a recent public-market entrant, having listed on the Nasdaq in September 2025, and its investor narrative is dominated by its rapid post-IPO re-rating, a large institutional stake, and its exposure to AI-driven data center and life sciences construction demand. The debate around the stock now centers on whether the company can convert its strong top-line momentum and backlog into durable profitability, given its leveraged balance sheet and a share price that has swung violently since listing.…
LGN
Legence Corp. Class A Common stock
$56.65
Related headlines
Investment Opinion: Should I buy LGN Today?
Based on the synthesis of data, the recommendation is a Hold with a speculative bias. The core thesis is that Legence's explosive revenue growth (105% YoY) and robust free cash flow ($297.1 million TTM) are offset by severe margin compression (gross margin of 14.4%) and a leveraged balance sheet (debt-to-equity of 2.43x), creating a high-risk, high-reward profile. The analyst consensus is strong buy with an average target of $102.53, implying 81% upside, but the current price of $56.65 reflects deep skepticism about profitability.
Supporting evidence includes the forward PE of 23.3x, which is reasonable if EPS estimates of $4.73 are met, and the price-to-sales ratio of 1.00x, near the low end of its post-IPO range. However, the EV/EBITDA of 33.0x and price-to-book of 6.52x indicate a premium valuation relative to current profitability. The company's Q1 2026 net income of $16.1 million and operating cash flow of $120.1 million demonstrate improving fundamentals, but the gross margin decline from 20.9% in Q3 2025 to 14.4% in Q1 2026 is a red flag. The PEG ratio of 0.037 suggests the stock is cheap relative to growth, but this relies on aggressive earnings estimates.
The biggest risks are margin deterioration, integration challenges from $281.3 million in Q1 acquisitions, and a potential slowdown in data center spending. The rating would upgrade to Buy if gross margins stabilize above 18% and operating margins exceed 5%, or downgrade to Sell if revenue growth decelerates below 20% or if the company misses EPS estimates. Relative to its history, the stock is undervalued on sales and cash flow but overvalued on book value and EBITDA; relative to peers, the forward PE premium of 40-50% is justified only by superior growth. Overall, the stock appears fairly valued to slightly undervalued for risk-tolerant investors.
Sign up to view all
LGN 12-Month Price Forecast
Legence presents a high-growth, high-risk opportunity with significant upside if margin recovery materializes. The stock's 34% three-month decline has compressed valuation multiples to near post-IPO lows, but the core issue of profitability remains unresolved. Analyst sentiment is overwhelmingly positive, yet the wide target range and lack of recent upgrades suggest caution. I would upgrade to bullish if Q2 2026 gross margins exceed 18% and operating margins expand above 5%, and downgrade to bearish if revenue growth falls below 20% or if debt levels increase further. The risk/reward is balanced, favoring a neutral stance until clearer evidence of sustainable profitability emerges.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Legence Corp. Class A Common stock's 12-month outlook, with a consensus price target around $102.53 and implied upside of +81.0% versus the current price.
Average Target
$102.53
0 analysts
Implied Upside
+81.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $130
Analyst target range
Coverage is robust for a recent IPO, with 17 analysts and a consensus recommendation of strong buy (recommendation mean of 1.24), and the average target price of $102.53 implies roughly 81% upside from the current price of $56.65. The consensus leans decisively bullish, and the estimated EPS average of $4.73 — with a tight range of $4.53 to $4.87 — suggests analysts see a clear path to profitability, while estimated revenue of $7.17 billion (range $6.94B to $7.34B) implies continued top-line expansion. The wide gap between the current price and the average target is unusual and signals either significant undervaluation or stale targets that have not yet been revised downward following the summer selloff. The target range spans $80.00 to $130.00, a spread of 62.5% of the midpoint, which signals high uncertainty; the high target of $130 assumes multiple expansion and successful integration of acquisitions alongside sustained data center demand, while the low target of $80 still implies 41% upside and prices in margin compression and slower backlog conversion rather than a bear-case collapse. Institutional ratings show a stable-to-positive pattern: Guggenheim, Tigress Financial, Goldman Sachs, Stifel, BMO Capital, and BTIG all maintain Buy or Outperform ratings as of mid-2026, with Barclays the lone Equal Weight, and no downgrades in the visible record — a constructive signal, though the absence of recent upgrades after the 34% decline suggests analysts are waiting for evidence of margin recovery before raising targets further.
Bulls vs Bears: LGN Investment Factors
The bull case rests on explosive revenue growth (105% YoY), a robust backlog, and a forward PE of 23.3x that appears cheap relative to expected EPS of $4.73, with analysts projecting 81% upside. The bear case centers on severe margin compression (gross margin down to 14.4%), a leveraged balance sheet (debt-to-equity of 2.43x), and negative trailing earnings that make the valuation difficult to justify on current profitability. Currently, the bear evidence is stronger on near-term fundamentals, but the bull case has more potential if margin recovery materializes. The single most important tension is whether Legence can convert its surging revenue into sustainable profitability—if gross margins stabilize above 18% and operating margins expand, the stock could re-rate toward analyst targets; if margin pressure persists, the downside could be significant.
Bullish
- Explosive revenue growth: Q1 2026 revenue reached $1.038 billion, up 105.1% year-over-year from $506.0 million, and up 40.7% sequentially from $737.6 million in Q4 2025. This accelerating top-line momentum, driven by the Installation and Maintenance segment ($872.1 million), demonstrates strong demand for Legence's critical building systems expertise.
- Massive analyst upside: The consensus average target price of $102.53 implies 81% upside from the current $56.65, with 17 analysts covering the stock and a strong buy consensus (recommendation mean of 1.24). Even the lowest target of $80.00 implies 41% upside, suggesting the selloff has created a wide margin of safety.
- Attractive forward valuation: The forward PE of 23.3x is reasonable given the consensus FY EPS estimate of $4.73 and a PEG ratio of 0.037, which signals the multiple is cheap relative to expected growth. The price-to-sales ratio of 1.00x and price-to-free-cash-flow of 9.95x are near the bottom of the post-IPO range, down from 3.65x and 37.1x respectively in Q1 2026.
- Robust free cash flow: Trailing free cash flow is $297.1 million, with Q1 2026 FCF of $102.3 million on $120.1 million of operating cash flow. Cash at period end was $244.6 million, providing internal funding capacity despite a leveraged balance sheet.
Bearish
- Severe margin compression: Gross margin fell to 14.4% in Q1 2026 from 20.0% in Q4 2025 and 20.9% in Q3 2025, while revenue surged 105% YoY. This suggests Legence is winning large fixed-price projects at lower margins, and the 3.6% operating margin and 5.6% EBITDA margin leave little cushion for cost overruns.
- Heavy debt burden: Debt-to-equity stands at 2.43x and total debt to capitalization is 70.0%, with Q1 2026 interest expense of $17.0 million. The current ratio of 1.57 is adequate but not fortress-like, and the -15.2% ROE reflects the cumulative drag of prior losses.
- Negative trailing earnings: The trailing PE of -42.6x is not meaningful because the company reported a net loss over the trailing period, with a net margin of -2.34%. Although Q1 2026 net income was positive at $16.1 million, the swing from a -$32.7 million loss in Q4 2025 highlights earnings volatility.
- Extreme price volatility: The stock is down 34.1% over three months and 17.5% over one month, with a maximum drawdown of -49.8% from its 52-week high of $107.24. Relative strength versus the S&P 500 is -37.2% over three months, indicating significant underperformance and risk.
LGN Technical Analysis
Legence is in a volatile recovery phase following a severe drawdown, with the stock up 3.1% over the trailing year but still 47.2% below its 52-week high of $107.24 and 110.1% above its 52-week low of $26.96. At the current price of $56.65, the shares are trading at roughly 52.9% of their 52-week range — squarely in the middle of the band — which reflects a market that has neither fully repriced the post-IPO euphoria nor capitulated to the summer selloff. The 6-month change of +11.3% and year-to-date gain of +26.8% confirm the longer-term trend remains positive despite the recent damage, though the -49.8% maximum drawdown underscores how punishing the correction has been for holders who bought near the highs. Recent momentum is decisively negative and diverging sharply from the longer-term trend: the stock is down 17.5% over the past month and 34.1% over three months, versus a 1-month gain of just 5.8% in the latest session and a flat-to-negative SPY (-1.1% over one month). Relative strength is deeply negative across short horizons — -16.5% versus the S&P 500 over one month and -37.2% over three months — signaling that Legence has been a significant source of underperformance even as the broader market held up, though the +14.7% YTD relative strength shows it was a leader earlier in the year. The stock's 3.14 short ratio and 1.26 million share volume indicate moderate short interest and liquidity, leaving room for sharp squeezes on positive catalysts but also for continued air pockets if sentiment sours. Key technical levels are well defined: support sits at the 52-week low of $26.96, with the recent August-September base around $51-$53 acting as a nearer-term floor, while resistance is the 52-week high of $107.24, with the $80-$90 zone representing the broken uptrend line and prior consolidation shelf. A breakout above $80 would signal that the summer correction was a shakeout and re-open the path toward the highs, whereas a breakdown below $51 would confirm a lower-high structure and likely target the $40s or the 52-week low; with no beta provided, volatility must be inferred from the -49.8% max drawdown and the 34% three-month decline, both of which imply far greater risk than the broad market.
Beta
—
—
Max Drawdown
-49.8%
Largest decline past year
52-Week Range
$28-$107
Price range past year
Annual Return
—
Cumulative gain past year
| Period | LGN Return | S&P 500 |
|---|---|---|
| 1m | -17.5% | -1.6% |
| 3m | -34.1% | +1.3% |
| 6m | +11.3% | +13.9% |
| 1y | — | +16.3% |
| ytd | +26.8% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LGN Fundamental Analysis
Legence's revenue trajectory is one of strong sequential expansion with a recent growth inflection: Q1 2026 revenue reached $1.038 billion, up 105.1% year-over-year from $506.0 million in Q1 2025, and up 40.7% sequentially from $737.6 million in Q4 2025. The quarterly progression — $506.0M, $598.9M, $708.0M, $737.6M, and $1.038B — shows accelerating top-line momentum, and segment data confirms the mix: Installation and Maintenance generated $872.1 million while Engineering and Consulting contributed $165.8 million, meaning the labor-intensive installation business is the primary growth engine. This trajectory implies the investment case rests on execution capacity and backlog conversion rather than demand, but the lumpy, fixed-price nature of the work means revenue growth can mask margin and cash-flow volatility. Profitability is thin and inconsistent: Q1 2026 net income was $16.1 million on a 1.55% net margin, a sharp swing from the -$32.7 million loss in Q4 2025 and the -$0.6 million loss in Q3 2025, while gross margin compressed to 14.4% in Q1 2026 from 20.0% in Q4 2025 and 20.9% in Q3 2025. The gross margin decline alongside surging revenue suggests the company is winning large fixed-price projects at lower margins, and the 3.6% operating margin and 5.6% EBITDA margin remain well below what best-in-class engineering and construction peers typically earn, leaving little cushion for cost overruns. The balance sheet carries meaningful risk: debt-to-equity stands at 2.43x, total debt to capitalization is 70.0%, and the current ratio of 1.57 is adequate but not fortress-like, while the -15.2% ROE reflects the cumulative drag of prior losses. Positively, free cash flow is robust — $297.1 million on a trailing basis, with Q1 2026 FCF of $102.3 million on $120.1 million of operating cash flow — and cash at period end was $244.6 million, giving the company internal funding capacity, though the $281.3 million of Q1 acquisitions and $193.4 million of debt repayment show capital allocation is aggressive and leverage-dependent.
Quarterly Revenue
$1.0B
2026-03
Revenue YoY Growth
+105.1%
YoY Comparison
Gross Margin
14.4%
Latest Quarter
Free Cash Flow
$297126000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LGN Overvalued?
Because Legence reported positive net income in the most recent quarter but a negative trailing figure, the trailing PE of -42.6x is not meaningful; the appropriate primary metric is the forward PE of 23.3x, supported by the price-to-sales ratio of 1.00x and EV/Sales of 1.44x. The gap between the negative trailing PE and the 23.3x forward PE implies the market expects a dramatic earnings inflection, consistent with the consensus FY EPS estimate of $4.73 and the PEG ratio of 0.037, which suggests the forward multiple is cheap relative to expected growth if those estimates are met. However, the EV/EBITDA of 33.0x and price-to-book of 6.52x indicate the market is already paying a substantial premium for the asset base and cash flows. Peer comparison is constrained by the absence of an industry-average valuation dataset, but within the engineering and construction sector, a 1.00x PS and 1.44x EV/Sales are near the middle of the range for specialty contractors, while the 6.52x P/B and 33.0x EV/EBITDA sit at the high end and imply investors are capitalizing future margin expansion rather than current profitability. The forward PE of 23.3x versus a sector where many peers trade in the mid-teens suggests a premium of roughly 40-50%, which can only be justified by Legence's superior growth (105% YoY revenue) and its data center and life sciences exposure. Historically, the stock's own valuation band has compressed dramatically: PS ratio fell from 3.65x in Q1 2026 to 1.00x currently, and P/B dropped from 7.50x to 6.52x, while the price-to-free-cash-flow ratio sits at 9.95x versus 37.1x in Q1 2026 — meaning the shares are now near the bottom of their post-IPO valuation range on sales and cash flow. That compression reflects the 34% three-month decline rather than fundamental deterioration, and it creates a setup where either the market is pricing in a genuine growth slowdown or the stock has been oversold relative to its earnings power.
PE
-42.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.0x
Enterprise Value Multiple
Investment Risk Disclosure
Legence faces significant financial and operational risks. The company's debt-to-equity ratio of 2.43x and total debt to capitalization of 70.0% indicate a heavily leveraged balance sheet, with Q1 2026 interest expense of $17.0 million consuming a substantial portion of operating income. Gross margin compression to 14.4% in Q1 2026 from over 20% in prior quarters suggests that the company is sacrificing profitability for growth, and the 3.6% operating margin leaves minimal buffer against cost overruns on fixed-price contracts. Additionally, the -15.2% ROE and negative trailing net margin of -2.34% highlight the cumulative drag of prior losses and the challenge of achieving consistent profitability.
Market and competitive risks are also pronounced. The stock trades at a premium valuation on some metrics, with a price-to-book of 6.52x and EV/EBITDA of 33.0x, which could compress if growth slows or margins fail to recover. The absence of a beta in the data makes it difficult to quantify market correlation, but the -49.8% maximum drawdown and 34.1% three-month decline imply far greater volatility than the broad market. Competitive pressures in the engineering and construction sector are intense, and Legence's focus on fixed-price contracts exposes it to pricing risk and project execution issues. Recent news of an 80% post-IPO surge and a $24 million institutional bet highlights sentiment risk, as any disappointment could trigger a sharp reversal.
The worst-case scenario would involve a continued decline in gross margins, failure to integrate recent acquisitions, and a slowdown in data center and life sciences construction spending. In this scenario, the stock could retest its 52-week low of $26.96, representing a 52.4% decline from the current price of $56.65. Even the analyst low target of $80.00 implies 41% upside, but if targets are revised downward, the downside could be severe. A breakdown below the recent base of $51-$53 would confirm a lower-high structure and likely target the $40s or the 52-week low, resulting in a potential loss of 30-50% from current levels.
FAQ
The most severe risk is margin compression, with gross margins falling to 14.4% in Q1 2026 from 20.9% in Q3 2025, which could continue if the company wins lower-margin projects. Financial risk is high due to a debt-to-equity ratio of 2.43x and interest expense of $17.0 million in Q1 2026, which consumes a large portion of operating income. Competitive risk includes the fixed-price nature of contracts, exposing Legence to cost overruns and pricing pressure in the engineering and construction sector. Macro risk is significant given the stock's -49.8% maximum drawdown and 34.1% three-month decline, indicating high volatility and sensitivity to sentiment shifts. Company-specific risk includes the integration of $281.3 million in Q1 acquisitions, which may not deliver expected synergies.
The 12-month forecast has three scenarios: bull case (30% probability) targets $102.53-$130.00, assuming gross margin recovery above 18% and sustained 50%+ revenue growth; base case (50% probability) targets $80.00-$102.53, assuming moderate margin recovery to 16-17% and 30-40% revenue growth; bear case (20% probability) targets $26.96-$80.00, assuming continued margin compression and a slowdown in data center spending. The base case is most likely, hinging on the company's ability to stabilize gross margins and meet EPS estimates of $4.73. Key catalysts include Q2 2026 earnings, acquisition integration, and data center demand trends.
LGN appears undervalued on forward earnings and sales but overvalued on asset-based metrics. The forward PE of 23.3x is a premium to the sector's mid-teens, but the PEG ratio of 0.037 and price-to-sales of 1.00x are near the low end of the post-IPO range, down from 3.65x in Q1 2026. The EV/EBITDA of 33.0x and price-to-book of 6.52x indicate the market is capitalizing future margin expansion rather than current profitability. Relative to its own history, the stock is cheap on sales and cash flow, but the negative trailing PE of -42.6x makes it difficult to value on earnings. The market appears to be pricing in a successful turnaround, with significant upside if margins recover.
LGN is a speculative buy for risk-tolerant investors, with 81% upside to the analyst average target of $102.53. The stock trades at a forward PE of 23.3x, which is reasonable if EPS estimates of $4.73 are met, and the PEG ratio of 0.037 suggests undervaluation relative to growth. However, the biggest downside risk is margin compression, with gross margins falling to 14.4% in Q1 2026, and a leveraged balance sheet (debt-to-equity of 2.43x). For long-term investors with a high risk tolerance, the secular data center tailwind and robust free cash flow ($297.1 million TTM) make it a compelling opportunity, but position sizing should be conservative given the -49.8% maximum drawdown.
LGN is more suitable for long-term investment (minimum 2-3 years) given its early-stage growth profile, high volatility, and the need for margin recovery to materialize. The stock has no dividend (payout ratio of 0) and a short ratio of 3.14, indicating moderate short interest that could lead to squeezes. The -49.8% maximum drawdown and 34.1% three-month decline make it unsuitable for short-term traders unless they can actively manage risk. Earnings visibility is low due to lumpy fixed-price contracts, but the secular data center and life sciences tailwinds provide a multi-year growth runway. A minimum holding period of 2-3 years allows time for acquisitions to integrate and margins to normalize.